← All indications
Graft Rejection
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Drugs by status
Approved for this indication (4)
Phase 4 trials (33)
- montelukast
- vitamin d3
- methylprednisolone
- prednisone
- eculizumab
- fosfomycin
- tacrolimus
- insulin human
- motexafin gadolinium
- belatacept
- caffeine
- immune globulin (human)
- sirolimus
- mycophenolate
- sulfamethoxazole
- everolimus
- tocilizumab
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- as03
- inactivated influenza vaccine
- losartan
- azithromycin
- budesonide
- midazolam
- regadenoson
- rituximab
- tromethamine
- basiliximab
- trimethoprim
- +3 more
Phase 2 trials (18)
Phase 1 trials (7)